Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin

Catalyst Pharmaceuticals (CPRX) has reached a critical patent litigation settlement with Lupin Pharmaceuticals, preventing Lupin from marketing a generic version of its key drug, Firdapse, in the U.S. until February 25, 2035. This agreement significantly protects CPRX's primary revenue stream, as Firdapse accounted for 62% of the company's net product sales in 2024, safeguarding its top line from generic erosion. While this resolves a major challenge, Catalyst Pharmaceuticals still faces ongoing patent litigation with Hetero regarding Firdapse and anticipates generic competition for its secondary product, Fycompa, beginning in 2025.

Analysis

Catalyst Pharmaceuticals (CPRX) has materially de-risked its primary revenue stream through a settlement with Lupin Pharmaceuticals, which prevents a generic version of Firdapse from entering the U.S. market until February 25, 2035. This development is critical, as Firdapse constitutes the majority of the company's top line, accounting for 62% of net product sales in 2024 and generating $168.6 million in the first half of 2025. While this agreement, following similar ones with Teva and Inventia, provides significant long-term revenue protection, key risks persist. The patent litigation concerning Firdapse against another generic manufacturer, Hetero, remains ongoing and represents a lingering threat to the drug's market exclusivity. Furthermore, the company faces a near-term revenue headwind from its secondary product, Fycompa, whose patents are set to expire in 2025 and 2026, which is expected to cause a significant sales decline due to generic entry. This situation heightens the company's reliance on Firdapse and the commercial execution of its newer asset, Agamree, to offset the impending Fycompa revenue erosion. The stock's year-to-date underperformance of -1.2% versus the industry's +10.2% growth suggests the market has been weighing these litigation risks and portfolio challenges.

Key Decisions for Investors

• Consider the settlement a significant positive catalyst that improves long-term cash flow visibility for Firdapse, potentially justifying a re-evaluation of CPRX's valuation given its recent market underperformance.
• Investors should closely monitor developments in the outstanding patent litigation with Hetero, as an unfavorable outcome could materially alter Firdapse's competitive landscape and the company's financial outlook.
• Focus on the company's strategy to mitigate the impending revenue loss from Fycompa's patent expirations in 2025-2026, particularly the sales trajectory of Agamree and any new business development activities aimed at diversification.